Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Healthequity (HQY) EBITDA Margin (2016 - 2026)

Healthequity has reported EBITDA Margin over the past 14 years, most recently at 21.24% for Q1 2026.

  • For Q1 2026, EBITDA Margin rose 1279.0% year-over-year to 21.24%; the TTM value through Jan 2026 reached 22.33%, up 1427.0%, while the annual FY2026 figure was 24.55%, 1649.0% up from the prior year.
  • EBITDA Margin for Q1 2026 was 21.24% at Healthequity, down from 24.43% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 27.5% in Q3 2025 and troughed at 16.14% in Q1 2022.
  • A 5-year average of 6.76% and a median of 5.89% in 2023 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: tumbled -1900bps in 2022 and later skyrocketed 2253bps in 2025.
  • Year by year, EBITDA Margin stood at 0.76% in 2022, then skyrocketed by 875bps to 5.89% in 2023, then tumbled by -68bps to 1.9% in 2024, then soared by 1187bps to 24.43% in 2025, then fell by -13bps to 21.24% in 2026.
  • Business Quant data shows EBITDA Margin for HQY at 21.24% in Q1 2026, 24.43% in Q4 2025, and 27.5% in Q3 2025.